| | |
CD68
|
P value
|
CD163
|
P value
|
|---|
|
1
|
2
|
3
|
1
|
2
|
3
|
|---|
|
Age category
|
< 45 years
|
31%
|
30%
|
11%
|
0.5
|
29%
|
31%
|
12%
|
0.05*
|
|
≥ 45 years
|
10%
|
11%
|
7%
|
8%
|
9%
|
11%
|
|
Gender
|
Male
|
10%
|
19%
|
8%
|
0.5
|
9%
|
14%
|
14%
|
0.02*
|
|
Female
|
31%
|
22%
|
10%
|
28%
|
26%
|
9%
|
|
HB category
|
< 10.5 g/dl
|
17%
|
13%
|
6%
|
0.6
|
16%
|
30%
|
10%
|
0.17
|
|
≥ 10.5 g/dl
|
24%
|
28%
|
12%
|
21%
|
27%
|
13%
|
|
WBCs category
|
< 15 × 109/l
|
35%
|
34%
|
16%
|
0.8
|
30%
|
35%
|
20%
|
0.7
|
|
≥ 15× 109/l
|
6%
|
7%
|
2%
|
7%
|
5%
|
3%
|
|
Albumin level
|
< 4 g/dl
|
16%
|
14%
|
5%
|
0.9
|
15%
|
10%
|
10%
|
0.03*
|
|
≥ 4 g/dl
|
24%
|
21%
|
7%
|
|
20%
|
27%
|
5%
|
|
HCV virology
|
Negative
|
35%
|
34%
|
14%
|
0.4
|
32%
|
34%
|
20%
|
0.9
|
|
Positive
|
6%
|
7%
|
1%
|
5%
|
6%
|
3%
|
|
B symptoms
|
Absent
|
23%
|
15%
|
8%
|
0.2
|
23%
|
16%
|
7%
|
0.04*
|
|
Present
|
18%
|
16%
|
10%
|
14%
|
24%
|
16%
|
|
Bulky disease
|
No
|
40%
|
37%
|
12%
|
0.005*
|
36%
|
37%
|
16%
|
0.005*
|
|
Yes
|
1%
|
4%
|
6%
|
1%
|
3%
|
7%
|
|
Histopathology subtype
|
LR
|
4%
|
7%
|
1%
|
0.5
|
5%
|
4%
|
3%
|
0.86
|
|
MC
|
21%
|
18%
|
7%
|
16%
|
21%
|
9%
|
|
NS
|
16%
|
16%
|
10%
|
16%
|
15%
|
11%
|
|
Extra nodal disease
|
No
|
34%
|
25%
|
14%
|
0.07
|
29%
|
27%
|
17%
|
0.55
|
|
Yes
|
7%
|
16%
|
4%
|
8%
|
13%
|
6%
|
|
Stage
|
Limited
|
14%
|
4%
|
3%
|
0.02*
|
13%
|
6%
|
2%
|
0.02*
|
|
Advanced
|
27%
|
37%
|
15%
|
24%
|
34%
|
21%
|
|
IPS
|
< 3
|
30%
|
23%
|
7%
|
0.04*
|
25%
|
27%
|
8%
|
0.02*
|
|
≥ 3
|
11%
|
18%
|
11%
|
12%
|
13%
|
15%
|
|
ORR
|
CR/PR
|
38%
|
24%
|
11%
|
0.001*
|
34%
|
28%
|
11%
|
0.001*
|
|
NO CR/PR
|
3%
|
17%
|
7%
|
3%
|
12%
|
12%
|
- HB hemoglobin, WBC white blood cell count, HCV Hepatitis C virus, MC mixed cellularity, NS nodular sclerosis, LR lymphocyte rich, IPS International Prognostic score, ORR overall response rate, CR complete response, PR partial response
